# Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma

> **NCT07543510** · NA · NOT_YET_RECRUITING · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 38 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Atezolizumab Plus Bevacizumab
- Transarterial Chemoembolization

## Interventions

- **DRUG:** TACE-HAIC + Atezolizumab + Low-dose Bevacizumab

## Key facts

- **NCT ID:** NCT07543510
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07543510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07543510, "Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07543510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*